Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Treated With Hemodialysis (PEARL-HD)

NCT03781089 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT03781089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Treated With Hemodialysis (PEARL-HD)
Lead sponsor
Duke University
Phase
Phase 4
Overall status
Completed
Start date
June 20, 2019
Completion date
March 15, 2023
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, hyperkalemia